Pharmacokinetics of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in Japanese chronic kidney disease patients on dialysis

Japanese Pharmacology and Therapeutics

Volumn 38, Issue 12, 2010, Pages 1175-1190

  Hayashi, Terumasa ^a   Kobayashi, Takeshi ^b   Kukita, Kazutaka ^c   Miyazaki, Shigeru ^d   Suzuki, Hiromichi ^e   Kubota, Minora ^f   Sasaoka, Takuo ^g   Kinugasa, Eriko ^h   Kanno, Yutaka ^i,j   Seno, Hachiro ^k,l   Ono, Toshihiko ^m   Kobayashi, Hiroyuki ^n,o   Inariba, Hiromi ^p,q   Tabata, Tsutomu ^r,s   Kakiya, Ryusuke ^s,t   Hiramatsu, Makoto ^u   Kawanishi, Hideki ^v   Moriishi, Misaki ^w   Minakuchi, Jun ^x   Hori, Kei ^y   Bessho, Masami ^e   Suzuki, Masashi ^d   more..

^a Department of Cardiology   (Japan)

^b Kitasaito Hospital   (Japan)

^c SAPPORO HOKUYU HOSPITAL   (Japan)

^d Shinrakuen Hospital   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f Ouji Hospital   (Japan)

^g Yokosuka Clinic   (Japan)

^h SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

ⁱ Specified Medical Corporation Jisenkai Aizawa Hospital   (Japan)

^j Kanno Dialysis and Vascular Access Clinic   (Japan)

^k Kaikoukai Central Clinic   (Japan)

^l Kakegawa Kyoritsu Clinic   (Japan)

^m Tojinkai Hospital   (Japan)

ⁿ Tojinkai Hospital Fuzoku Shinnryojo   (Japan)

^o Karasuma Dialysis Clinic   (Japan)

^p Ohno Memorial Hospital   (Japan)

^q Shimada Clinic   (Japan)

^r Inoue Hospital Clinic   (Japan)

^s Inoue Hospital   (Japan)

^t Meijibashi Hospital   (Japan)

^u OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^v TSUCHIYA GENERAL HOSPITAL   (Japan)

^w Nakajima Tsuchiya Clinic   (Japan)

^x Kawashima Hospital   (Japan)

^y Department of Surgery   (Japan)

more..

Author keywords

C. E. R. A.; CERA; Epoetin; Epoetin beta pegol (genetical recombination); Erythropoietin; ESA; Hemodialysis; Japanese; Long acting; MICERA; PEG; Peritoneal dialysis; Pharmacodynamics; Pharmacokinetics; Phase ii; Polyethylene glycol; Ro50 3821; Safety

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; JAPANESE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); RENAL REPLACEMENT THERAPY; SINGLE DRUG DOSE;

EID: 79951536545     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator) : a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005 ; 4 : 436-40.
2. Locatelli F, Reigner B. C. E. R. A. : pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007 : 16 : 1649-61.
3. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006 ; 368 : 947-53. (Pubitemid 44331359)
4. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis : a randomized trial. Am J Kidney Dis 2007 ; 50 : 989-1000. (Pubitemid 350122810)
5. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, et al. ; PROTOS Study Investigators. Once-monthly subcutaneous C. E. R. A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007 ; 2 : 637-46.
6. Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, et al. ; MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis : a randomised non-inferiority trial (MAXIMA). Lancet 2007 ; 370 : 1415-21.
7. Tanaka T, Sunami Y, Fujisaki K, Irie S, Hirashima K. A phase I clinical study of Ro50-3821 : a single subcutaneous dose study. Jpn Pharmacol Ther 2010 ; 38 : 1145-57.
8. Yamazaki C, Watanabe Y, Sakamoto N. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients. Jpn J Nephrol 1993 ; 35 : 1233-42. (Pubitemid 24023035)
9. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002 ; 69 : 265-74. (Pubitemid 36005815)